OTCMKTS:EUCRU Eucrates Biomedical Acquisition (EUCRU) Stock Price, News & Analysis $10.02 +0.01 (+0.10%) As of 04/26/2023 Add Share Share Stock Analysis Stock Analysis About Eucrates Biomedical Acquisition Stock (OTCMKTS:EUCRU) Get EUCRU alerts:Sign Up Key Stats Today's Range$10.01▼$10.0250-Day Range$10.02▼$10.0252-Week Range$9.76▼$10.66Volume21,500 shsAverage Volume1,921 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Eucrates Biomedical Acquisition Corp. is a special purpose acquisition company formed to identify and complete a business combination with a company in the biomedical, biotechnology, pharmaceutical or broader healthcare sectors. As a blank-check company, Eucrates Biomedical Acquisition did not operate a conventional business or market its own products and services. Its activities were focused on raising capital and seeking a merger, acquisition or similar transaction with a target company. The company offered units under the symbol EUCRU, with the units consisting of shares and associated warrants. Publicly available information about its target, operating activities, geographic presence and leadership is limited.AI Generated. May Contain Errors. Read More Receive EUCRU Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eucrates Biomedical Acquisition and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EUCRU Stock News HeadlinesPsyence Biomed halts Clairvoyant Therapeutics acquisitionOctober 6, 2024 | investing.comEucrates Biomedical Acquisition announces liquidationApril 11, 2023 | seekingalpha.comTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of Saudi Arabia's largest oil field, with potential to last two million years. While the One Big Beautiful Bill Act eliminated federal credits for solar, wind, and EVs, this energy source was reclassified alongside oil and nuclear power and given eight years of tax credits. Google signed a 15-year contract, and Bill Gates committed $100 million. One company controls the entire supply chain behind this discovery.October 16 at 1:00 AM | Behind the Markets (Ad)Eucrates Biomedical Acquisition Corp. Announces LiquidationApril 11, 2023 | finance.yahoo.comBiomedical Sensors Market will surpass USD 21.3 billion by 2030 at a CAGR of 16% till 2030 : GreyViewsJanuary 30, 2023 | finance.yahoo.comLove Island 2023: First contestant revealed as stunning biomedical student TanyaJanuary 25, 2023 | mirror.co.ukMBiomedical EngineerJanuary 11, 2023 | money.usnews.comCenterline Biomedical announces Gulam Khan as Chief Executive OfficerOctober 6, 2022 | markets.businessinsider.comSee More Headlines EUCRU Stock Analysis - Frequently Asked Questions How have EUCRU shares performed this year? Eucrates Biomedical Acquisition's stock was trading at $10.02 at the start of the year. Since then, EUCRU shares have increased by 0.0% and is now trading at $10.02. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorN/A Industry N/A Sub-IndustryN/A Current SymbolOTCMKTS:EUCRU CIK1822929 WebN/A Phone(212) 710-5220FaxN/AEmployees4Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (OTCMKTS:EUCRU) was last updated on 4/26/2023 by MarketBeat.com Staff. From Our PartnersElon Musk’s 4th Wealth Window Set to Open by October 30Jeff Brown, the analyst who flagged Bitcoin, Tesla, and Nvidia early, is tracking Elon Musk's next move. He po...Brownstone Research | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredSpaceX minted 4400 millionaires in a single daySpaceX minted 4,400 millionaires in a single day, and Tesla has turned more than 5,000 employees into milliona...Behind the Markets | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | SponsoredA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...Investors Alley | SponsoredUndiscovered Sub-$1 Gold-Silver Royalty Stock Takes FlightA small-cap gold and silver royalty company is generating record revenue from producing mines, yet shares stil...Digest Publishing | SponsoredINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...Paradigm Press | SponsoredThis high yielding “gold annuity” is starting to move…Garrett Goggin, a 20+ year gold analyst, has called major moves before: Montage Gold up 2,567%, G2 Goldfields ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eucrates Biomedical Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eucrates Biomedical Acquisition With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.